Roivant Sciences News - August 27, 2026
Roivant Announces FDA Approval for LISRAYA™, a New Dermatomyositis Treatment
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...
Roivant Secures FDA Approval for First Targeted Dermatomyositis Therapy
The U.S. Food and Drug Administration (FDA) approved LISRAYA (brepocitinib) for adults with dermatomyositis. Roivant Sciences' subsidiary, Priovant...
Roivant's Brepocitinib Clears Skin in Phase 3, Targeting 2026 FDA Approval
Priovant Therapeutics, a Roivant Sciences subsidiary, published skin-specific Phase 3 VALOR trial results for brepocitinib in JAMA Dermatology. The study...